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Vitamin D, insulin resistance, and 
renal disease
A Remuzzi1
Chonchol and Scragg report the results of a population study on 
levels of 25-hydroxyvitamin D in patients with renal dysfunction. They 
demonstrate that these patients do not show vitamin D deficiency 
unless renal function is severely affected (GFR<29 mL/min/1.73m2), 
while vitamin D and renal function loss are independently associated 
with insulin resistance. These data provide more solid evidence than 
previous available studies on small patient groups, and pose new 
questions about the mechanisms responsible for progressive renal 
disease as well as potential effects of vitamin D supplementation.
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Th e role of vitamin D defi ciency in sev-
eral pathological conditions has been the 
focus of several investigations in the last 
few years.1 Th e complexity of the biologi-
cal role of vitamin D metabolism makes it 
diffi  cult to clearly delineate the role of vita-
min D cascade in these pathophysiological 
systems. More evidence is now emerging 
on the role of vitamin D besides calcium 
and phosphate homeostasis. Th us, vitamin 
D is known also to regulate cell prolifera-
tion and diff erentiation and to modulate 
the immune system, and it is implicated in 
several endocrine functions (Figure 1).2 In 
light of this broad spectrum of biochemi-
cal reactions, and the fact that vitamin D 
is produced by numerous diff erentiated 
cells and tissues,3 it is likely that vitamin 
D is involved in several pathophysiologi-
cal processes. Among these, vitamin D 
seems to be implicated in progressive kid-
ney diseases; however, despite evidence of 
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secondary hyperparathyroidism and 
reduced bone density, there is no direct 
evidence on the mechanisms by which 
vitamin D is involved in the development 
and progression of chronic renal diseases.
According to several reported studies, 
serum levels of vitamin D are decreased 
in patients aff ected by kidney diseases, 
as compared with the general popula-
tion, in diff erent stages of renal-function 
loss.4 However, these studies, although 
they document kidney disease and renal 
function well, are restricted to a small 
number of patients. At variance, the arti-
cle by Chonchol and Scragg5 (this issue) 
provides some interesting data based on 
population data. To overcome the limita-
tions of studies in small groups of patients, 
Chonchol and Scragg collected data from 
the Th ird National Health and Nutrition 
Examination Survey (NHANES III). Th e 
authors clearly demonstrate, by appropri-
ate statistical analysis, that serum levels of 
25-hydroxyvitamin D, a measure of blood 
stores of vitamin D, are eff ectively reduced 
in uremic patients, but only when renal 
function is severely lost (glomerular fi ltra-
tion rate ranging from 15 to 29 ml/min/
1.73 m2) as compared with that of subjects 
with normal renal function, whereas in 
patients aff ected by only mild or moderate 
loss of renal function the serum level of 25-
hydroxyvitamin D is normal. In addition, 
the results of the statistical analysis showed 
that 25-hydroxyvitamin D levels and loss 
of renal function have indepen dent inverse 
associations with insulin resistance,5 sug-
gesting that the relation between vitamin 
D and insulin resistance, if any, still has 
to be elucidated in more detail. Th us, the 
results of this study make some important 
contributions to the understanding of the 
pathophysiological role of vitamin D in 
progressive renal diseases and its possible 
implication for pharmacological therapy. 
In addition, they should guide future 
investigations of the potential role of vita-
min D supplementation.
Th e theoretical possibility that vitamin 
D is involved in the pathophysiology of 
progressive renal disease is based on the 
fact that, besides secondary hyperpar-
athyroidism, this molecule is involved in 
other cellular and metabolic functions 
known to be altered in renal diseases. 
One mechanism that has been better 
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characterized in the progression of renal 
disease is the activation of the renin–angi-
otensin system. Relevant experimental 
and clinical observations demonstrate that 
the antagonism of the biological action of 
angiotensin II prevents or ameliorates 
renal structural and functional changes.6 
Th e observation that vitamin D acts as 
a negative endocrine regulator for the 
renin–angiotensin system7 would indi-
cate a potential involvement of vitamin D 
in the progressive loss of renal function. 
Another possible mechanism that could 
relate vitamin D and progression of renal 
disease is the involvement of vitamin D in 
cell cycle regulation and cell diff erentia-
tion.3 It is of interest that vitamin D sup-
plementation decreased podocyte loss 
and hypertrophy in the classical model of 
experimental renal disease progression, 
the surgical reduction of renal mass in the 
rat.8 Th ere is also experimental evidence 
that vitamin D is related to insulin resist-
ance,9 a condition frequently observed 
in patients aff ected by progressive renal 
disease. Finally, vitamin D is known to 
modulate the functioning of immune 
cells such as T lymphocytes and mono-
cytes,10 which are frequently involved in 
the immunological reactions associated 
with renal disease progression.
On the basis of this body of evidence 
and of these theoretical considerations, it 
has been suggested that vitamin D has a 
potential role in kidney disease progres-
sion and that consequently vitamin D 
supplementation should be adopted to 
prevent renal disease and cardiovascular 
events in these patients. Th e Kidney Dis-
ease Outcomes Quality Initiative guide-
lines also recommend measurements 
of 25-hydroxyvitamin D serum levels 
in patients with advanced chronic renal 
disease. However, the data provided by 
Chonchol and Scragg5 clearly indicate 
that serum levels of 25-hydroxyvita-
min D are not signifi cantly reduced in 
patients aff ected by renal disease unless 
the glomerular fi ltration rate is lower than 
29 ml/min/1.73 m2, suggesting a condi-
tion not characterized by vitamin D defi -
ciency until the disease is in the advanced 
stage. Th ese data pose two challenges. Th e 
fi rst is to identify the role of vitamin D 
in the pathophysiological mechanisms 
responsible for these diseases, especially 
in the initiation and the first stage of 
progression. Th e second is related to the 
potential eff ects of vitamin D supplemen-
tation therapy in these patients. On the 
basis of the data reported by Chonchol 
and Scragg,5 both these issues need to be 
further elucidated.
In addition, clinical data demonstrate 
benefi cial eff ects of vitamin D supplemen-
tation in these patients, even in the early 
phase of the disease.4 How this relates to 
the previously mentioned normal level 
of vitamin D should be studied in more 
detail. On the basis of this considera-
tion, vitamin D supplementation in these 
patients should be carefully evaluated 
in order to gain more evidence on the 
eff ective target of these therapies and the 
potential results that could be obtained 
in slowing the rate of renal disease pro-
gression. On the other hand, the data of 
Chonchol and Scragg5 do confi rm that 
vitamin D is defi cient in uremic patients 
in the advanced stage of the disease. Th ese 
results are important for the understand-
ing of the cardiovascular events that fre-
quently affect patients with end-stage 
renal disease. At the moment, deeper 
knowledge of the relative importance 
of the previously mentioned biological 
systems, linked to vitamin D, for the car-
diovascular morbidity and mortality in 
these patients is needed. Hopefully, the 
large-population data provided by Chon-
chol and Scragg5 will stimulate experi-
mental and clinical studies with the aim 
to investigate the eff ective role of vitamin 
D in the early phase of the disease, when 
serum levels of the vitamin D cascade are 
not signifi cantly aff ected, as well as in the 
late phase that is characterized by vitamin 
D defi ciency.
Finally, the results of Chonchol and 
Scragg5 also indicate that renal dysfunc-
tion and vitamin D have independent 
inverse associations with insulin resist-
ance, while in the general population 
there is evidence of close association 
between insulin sensitivity and serum 
levels of 25-hydroxyvitamin D. Thus, 
more complex mechanisms may relate 
these pathological manifestations, and 
more focused experimental and clinical 
research may help to elucidate them in 
the near future with the aim of avoiding 
unrealistic expectations for therapeutic 
approaches that have potential use in a 
large patient population.
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Figure 1 | Besides classical functions of vitamin D, there is now emerging evidence that other 
actions of this hormone are important in the regulation of organ and systemic functions.
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Insulin resistance and protein 
catabolism in non-diabetic 
hemodialysis patients
AJ O’Sullivan1,2 and JJ Kelly1
 Chronic kidney disease (CKD) is associated with complex metabolic 
changes including insulin resistance. Siew et al. have highlighted an 
important relationship between insulin resistance and skeletal muscle 
protein turnover. If insulin resistance is implicated in sarcopenia of CKD, 
further research will be required to determine whether interventions 
that improve insulin sensitivity improve clinical outcomes and 
cardiovascular risk in CKD.
Kidney International (2007) 71, 98–100. doi:10.1038/sj.ki.5002045
One of the most important predictive fac-
tors of survival on dialysis is the presence 
of malnutrition.1,2 Previous studies have 
demonstrated that a signifi cant propor-
tion of hemodialysis patients and chronic 
ambulatory peritoneal dialysis patients 
are malnourished. Th ese patients have 
increased morbidity and mortality and 
a poorer quality of life as compared with 
patients who are adequately nourished. 
Impaired nutrition may be measured by 
a variety of methods, but those methods 
that measure body composition directly 
(total-body nitrogen analysis and dual-
energy X-ray absorptiometry) demon-
strate that lean body mass is reduced in 
patients with renal impairment.3,4 Th ese 
changes are demonstrable at the initia-
tion of dialysis and are likely to develop 
in patients with mild to moderate chronic 
kidney disease (CKD). Negative nitro-
gen balance and sarcopenia can result 
from decreased protein anabolism or 
increased protein catabolism or both. 
Th e balance between these factors and 
relative contributions of other condi-
tions that cause sarcopenia are still to be 
defi ned. Decreased protein anabolism 
may result from disuse of muscles, sub-
optimal protein intake, intercurrent ill-
ness, and medications, whereas increased 
protein catabolism can result from acido-
sis, microinfl ammatory processes related 
to increased cytokines, oxidative stress, 
and the reduced actions of anabolic hor-
mones such as insulin.
Th e increased mortality and morbidity 
observed in dialysis patients with malnu-
trition or depleted muscle mass are princi-
pally due to an increase in cardiovascular 
events.5 In view of this, it is important 
not only to understand the mechanisms 
by which sarcopenia may occur, but also 
to understand the association between 
altered body composition and clinical out-
comes in CKD. Recent literature has high-
lighted the eff ects of chronic infl ammation 
and oxidative stress in predisposing CKD 
patients to malnutrition and increased vas-
cular disease.6 Chronic infl ammation may 
predispose to impaired nutritional status 
by enhancing protein catabolism. Asso-
ciations between chronic infl ammation, 
measured as elevated C-reactive protein 
or proinfl ammatory cytokines, impaired 
nutritional status, and subclinical and 
clinically overt vascular disease, have been 
documented in patients at the commence-
ment of dialysis. Furthermore, systemic 
infl ammation may result in reductions in 
total cholesterol levels, which may account 
for the altered epidemiological association 
of an inverse relationship between total 
cholesterol levels and mortality reported 
by some investigators in dialysis patients.
Although the malnutrition, inflam-
mation, atherosclerosis hypothesis may 
explain many of the clinical associations 
of malnutrition in dialysis patients,6 CKD 
is associated with complex metabolic 
changes, and Siew et al.7 (this issue) now 
highlight the importance of another meta-
bolic eff ect of CKD — insulin resistance. 
It is well documented that insulin resist-
ance is a feature of advanced CKD, and 
there is some evidence that insulin resist-
ance occurs in mild to moderate CKD. 
Th e cause of insulin resistance in non-
diabetic CKD is not apparent, but it may 
be related to central adiposity, the micro-
infl ammatory environment, or other met-
abolic defects. Insulin resistance has been 
shown to be an independent predictor of 
survival in dialysis patients.8 It has been 
hypothesized that insulin resistance may 
increase vascular risk in dialysis patients 
in the same way observed in the general 
population, because of the tendency of 
vascular risk factors to cluster in subjects 
who are insulin resistant.
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